MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review
Tara Behroozian,Daniel Goldshtein,Julie Ryan Wolf,Corina van den Hurk,Samuel Finkelstein,Henry Lam,Partha Patel,Lauren Kanee,Shing Fung Lee,Adrian Wai Chan,Henry Chun Yip Wong,Saverio Caini,Simran Mahal,Samantha Kennedy,Edward Chow,Pierluigi Bonomo,Tara Behroozian,Daniel Goldshtein,Julie Ryan Wolf,Corina van den Hurk,Samuel Finkelstein,Henry Lam,Partha Patel,Lauren Kanee,Shing Fung Lee,Adrian Wai Chan,Henry Chun Yip Wong,Saverio Caini,Simran Mahal,Samantha Kennedy,Edward Chow,Pierluigi Bonomo
DOI: https://doi.org/10.1016/j.eclinm.2023.101886
IF: 15.1
2023-03-29
EClinicalMedicine
Abstract:Summary Acute radiation dermatitis (ARD) commonly develops in cancer patients undergoing radiotherapy and is often characterized by erythema, desquamation, and pain. A systematic review was conducted to summarize the current evidence on interventions for the prevention and management of ARD. Databases were searched from 1946 to September 2020 to identify all original studies that evaluated an intervention for the prevention or management of ARD, with an updated search conducted in January 2023. A total of 235 original studies were included in this review, including 149 randomized controlled trials (RCTs). Most interventions could not be recommended due to a low quality of evidence, lack of supporting evidence, or conflicting findings across multiple trials. Photobiomodulation therapy, Mepitel® film, mometasone furoate, betamethasone, olive oil, and oral enzyme mixtures showed promising results across multiple RCTs. Recommendations could not be made solely based on the published evidence due to limited high-quality evidence. As such, Delphi consensus recommendations will be reported in a separate publication.